[New treatments for systemic diseases]

Arch Pediatr. 2006 Jun;13(6):596-8. doi: 10.1016/j.arcped.2006.03.033. Epub 2006 May 11.
[Article in French]
No abstract available

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic / immunology*
  • Antibodies, Antinuclear / blood
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / immunology*
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Bone Marrow Transplantation
  • Child
  • Drug Approval
  • Humans
  • IMP Dehydrogenase / antagonists & inhibitors*
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Nephritis / drug therapy*
  • Lupus Nephritis / immunology
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Rituximab
  • Tumor Necrosis Factor Inhibitors
  • Vasculitis / drug therapy*
  • Vasculitis / immunology

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Antinuclear
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Immunosuppressive Agents
  • Tumor Necrosis Factor Inhibitors
  • Rituximab
  • IMP Dehydrogenase
  • Mycophenolic Acid